


WHAT IS CLAIMED:

1. A compound having the structural Formula (I'):



(I')

or a pharmaceutically acceptable salt thereof, wherein:

X is a bond, C(R¹⁴)₂, O, S, SO, SO₂ or NH;

Y is CR⁹ or N, wherein when Y is N, Z is CR¹¹ and V is CR¹⁰;

V is CR¹⁰ or N, wherein when V is N, Z is CR¹¹ and Y is CR⁹;

Z is CR¹¹ or N, wherein when Z is N, V is CR¹⁰ and Y is CR⁹;

R¹ is a heterocycloalkyl, C₃-C₁₂cycloalkyl, aryl, C₁-C₆alkylaryl or when taken with R², and the nitrogen which they are bonded, forms nitrogen-containing ring, wherein the heterocycloalkyl, C₃-C₁₂cycloalkyl, aryl, C₁-C₆alkylaryl or nitrogen-containing ring is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, CN, OH, C₁-C₆alkoxy, C₁-C₆alkylOC₁-C₆alkyl, C₁-C₆alkylCOOH, COOH, oxo, COOC₁-C₆alkyl, C₁-C₆alkylCOOC₁-C₆alkyl, C₃-C₆cycloalkyl, C₁-C₆alkylC₃-C₆cycloalkyl, aryl, C₁-C₆alkyl, -C₁-C₆alkylOhaloC₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) and C₁-C₆alkylN(R⁷)(R⁸);

R² is hydrogen, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl or C₁-C₆alkylOH or when taken with R¹, and the nitrogen which they are bonded, forms a nitrogen-containing ring, wherein the nitrogen-containing ring is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, CN, OH, C₁-C₆alkoxy, C₁-C₆alkylOC₁-C₆alkyl, C₁-C₆alkylCOOH, COOH, oxo, COOC₁-C₆alkyl, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) and C₁-C₆alkylN(R⁷)(R⁸);

R³ is hydrogen, halogen, CN, OH, C₁-C₆alkoxy, C₁-C₆alkylOC₁-C₆alkyl, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOH, CON(R⁷)(R⁸), N(R⁷)(R⁸), C₁-C₆alkylN(R⁷)(R⁸), C₁-C₆alkyl(OCH₂CH₂)_nN(R⁷)(R⁸) or C₁-C₆alkylOhaloC₁-C₆alkyl or when taken
5 with R⁴ forms a C₃-C₆cycloalkyl or C₃-C₆heterocycloalkyl;

R⁴ is hydrogen, halogen, CN, OH, C₁-C₆alkoxy, C₁-C₆alkylOC₁-C₆alkyl, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOH, CON(R⁷)(R⁸), N(R⁷)(R⁸), C₁-C₆alkylN(R⁷)(R⁸), C₁-C₆alkyl(OCH₂CH₂)_nN(R⁷)(R⁸) or C₁-C₆alkylOhaloC₁-C₆alkyl or when taken
10 with R³ forms a C₃-C₆cycloalkyl or C₃-C₆heterocycloalkyl;

R⁵ is hydrogen, halogen, CN, OH, C₁-C₆alkoxy, C₁-C₆alkylOC₁-C₆alkyl, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) or C₁-C₆alkylN(R⁷)(R⁸) or when taken with R⁶ forms a C₃-C₆cycloalkyl or C₃-C₆heterocycloalkyl;
15

R⁶ is hydrogen, halogen, CN, OH, C₁-C₆alkoxy, C₁-C₆alkylOC₁-C₆alkyl, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) or C₁-C₆alkylN(R⁷)(R⁸) or when taken with R⁵ forms a C₃-C₆cycloalkyl or C₃-C₆heterocycloalkyl;

20 R⁷ is hydrogen, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOH, COC₁-C₆alkyl or COOC₁-C₆alkyl;

R⁸ is hydrogen, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOH, COC₁-C₆alkyl or COOC₁-C₆alkyl;
25

R⁹ is hydrogen, halogen, CN, OH, C₁-C₆alkoxy, C₁-C₆alkylOC₁-C₆alkyl, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) or C₁-C₆alkylN(R⁷)(R⁸);

30 R¹⁰ is hydrogen, halogen, CN, OH, C₁-C₆alkoxy, C₁-C₆alkylOC₁-C₆alkyl, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) or C₁-C₆alkylN(R⁷)(R⁸);

R¹¹ is hydrogen, halogen, CN, OH, C₁-C₆alkoxy, C₁-C₆alkylOC₁-C₆alkyl, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) or C₁-C₆alkylN(R⁷)(R⁸);

5

R¹² is hydrogen, halogen, CN, OH, C₁-C₆alkoxy, C₁-C₆alkylOC₁-C₆alkyl, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) or C₁-C₆alkylN(R⁷)(R⁸);

10 R¹³ is hydrogen, halogen, CN, OH, C₁-C₆alkoxy, C₁-C₆alkylOC₁-C₆alkyl, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) or C₁-C₆alkylN(R⁷)(R⁸);

each occurrence of R¹⁴ is independently selected from the group consisting of hydrogen, halogen,

15 CN, OH, C₁-C₆alkoxy, C₁-C₆alkylOC₁-C₆alkyl, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOH, CON(R⁷)(R⁸), N(R⁷)(R⁸) and C₁-C₆alkylN(R⁷)(R⁸);

n is 1, 2, 3 or 4; and

20 m is 0, 1 or 2.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 1 and X is O.

25 3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 1 and X is CH₂.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 0 and X is O.

30

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 1 and X is SO₂.

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 0 and X is $C(R^{14})_2$, wherein each occurrence of R^{14} is independently selected from the group consisting of hydrogen, halogen, OH, C₁-C₆alkoxy and C₁-C₆alkyl.

5


7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 1 and X is $C(R^{14})_2$, wherein each occurrence of R^{14} is independently selected from the group consisting of hydrogen, halogen, OH, C₁-C₆alkoxy and C₁-C₆alkyl.

10

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 0 and X is a bond.

9. The compound of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R^1 is selected from the group consisting of:

15



wherein R^1 is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of halogen, CN, OH, C₁-C₆alkoxy, C₁-C₆alkylOC₁-C₆alkyl, C₁-C₆alkylCOOH, COOH, oxo, COOC₁-C₆alkyl, C₃-C₆cycloalkyl, C₁-C₆alkylC₃-C₆cycloalkyl, aryl, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOhaloC₁-C₆alkyl, C₁-C₆alkylOH, CON(R^7)(R^8), N(R^7)(R^8) and C₁-C₆alkylN(R^7)(R^8);


20

R^7 is hydrogen, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl or C₁-C₆alkylOH; and

25

R^8 is hydrogen, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl or C₁-C₆alkylOH.


10. The compound of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R^1 is:



wherein R^1 is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of halogen, CN, OH, C_1 - C_6 alkoxy, C_1 - C_6 alkylOC $_1$ - C_6 alkyl, C_1 - C_6 alkylOhaloC $_1$ - C_6 alkyl, oxo, COOC $_1$ - C_6 alkyl, C_1 - C_6 alkyl, haloC $_1$ - C_6 alkyl and C_1 - C_6 alkylOH.

5

11. The compound of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein R^1 is:



wherein R^1 is unsubstituted or substituted with 1 to 5 substituents selected from the group consisting of halogen, CN, OH, C_1 - C_6 alkoxy, C_1 - C_6 alkylOC $_1$ - C_6 alkyl, C_1 - C_6 alkylOhaloC $_1$ - C_6 alkyl, oxo, COOC $_1$ - C_6 alkyl, C_1 - C_6 alkyl, haloC $_1$ - C_6 alkyl, NH_2 , and C_1 - C_6 alkylOH.

10


12. The compound of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein R^2 is hydrogen.

15

13. The compound of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein R^1 is taken with R^2 and the nitrogen to which they are bonded, to form a nitrogen-containing ring.

14. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein the nitrogen-containing ring is:

20



15. The compound of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein R^3 is hydrogen, C_1 - C_6 alkylOC $_1$ - C_6 alkyl or C_1 - C_6 alkyl or when taken with R^4 forms a C_3 - C_6 heterocycloalkyl.

25

16. The compound of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein R^3 is hydrogen or C₁-C₆alkyl or when taken with R^4 forms a C₃-C₆heterocycloalkyl.

5 17. The compound of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein R^5 is hydrogen or C₁-C₆alkyl.

18. The compound of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein R^6 is hydrogen or C₁-C₆alkyl.

10 19. The compound of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein R^3 and R^4 are independently selected from the group consisting of hydrogen, halogen, OH, C₁-C₆alkylOH, C₁-C₆alkylalkoxy, C₁-C₆alkylOC₁-C₆alkyl, C₁-C₆alkyl, C₁-C₆alkylOhaloC₁-C₆alkyl, CON(C₁-C₆alkyl)₂, C₁-C₆alkylN(R^7)(R^8) and C₁-C₆alkyl(OCH₂CH₂)_nN(R^7)(R^8);

15 R^7 is hydrogen, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOH, COC₁-C₆alkyl or COOC₁-C₆alkyl;

R^8 is hydrogen, C₁-C₆alkylCOOH, COOH, C₃-C₆cycloalkyl, C₁-C₆alkyl, haloC₁-C₆alkyl, C₁-C₆alkylOH, COC₁-C₆alkyl or COOC₁-C₆alkyl; and

20

n is 3.

20. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 1 or 2, R^{12} and R^{13} are independently selected from the group consisting of hydrogen, halogen, OH, C₁-C₆alkylOH, C₁-C₆alkylalkoxy and C₁-C₆alkylOC₁-C₆alkyl, C₁-C₆alkyl.

25

21. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is C(R^{14})₂, R^{14} is independently selected from the group consisting of hydrogen, halogen, OH, C₁-C₆alkylOH, C₁-C₆alkylalkoxy, C₁-C₆alkylOC₁-C₆alkyl and C₁-C₆alkyl.

30

22. The compound of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein Y is CH.

23. The compound of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein Z is CH.





5 24. The compound of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein V is CH.









25. The compound of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein Z is N and Y and V are both CH.









10









26. The compound of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein V is N and Y and Z are both CH.









27. A compound selected from the group consisting of:





































































































































































































































































































































































































and




;


or a pharmaceutically acceptable salt thereof.

28. A compound selected from the group consisting of






29. A compound selected from the group consisting of




5 pharmaceutically acceptable salt thereof.

30. A compound having the formula




31. A compound having the formula



5

32. A compound having the formula



33. A method for treating a *Plasmodium* infection, or for treating malaria, which
 10 comprises administering to a subject in need of such treatment a therapeutically effective amount of
 a compound of any one of claims 1-32, or a pharmaceutically acceptable salt thereof.

34. A method for inhibiting plasmepsin X which comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound of any one of claims 1-32, or a pharmaceutically acceptable salt thereof.

5 35. A method for inhibiting plasmepsin IX which comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound of any one of claims 1-32, or a pharmaceutically acceptable salt thereof.

10 36. A method for dual inhibition of plasmepsin X and plasmepsin X which comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound of any one of claims 1-32, or a pharmaceutically acceptable salt thereof.

15 37. The use of a compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-32 to treat a *Plasmodium* infection, or malaria in a patient in need thereof.

38. The use of a compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-32 to inhibit plasmepsin X in a patient in need thereof.

20 39. The use of a compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-32 to inhibit plasmepsin IX in a patient in need thereof.

40. The use of a compound, or pharmaceutically acceptable salt thereof, of claim 1 to inhibit plasmepsin IX and plasmepsin X, in a patient in need thereof.

25 41. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

42. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

30 43. A method for treating a *Plasmodium* infection, or for treating malaria, comprising administration of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and an effective amount of one or more additional anti-malarial agents.

44. A method for the treatment of malaria by inhibition of plasmepsin X, IX and at least one other mechanism, comprising administration of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and an effective amount of one additional anti-malarial agent, wherein the additional anti-malarial agent acts through a different mechanism than inhibiting plasmepsin IX or
5 plasmepsin X.